roniciclib

Ligand id: 7874

Name: roniciclib

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 116.57
Molecular weight 430.13
XLogP 3.85
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Roniciclib was assessed in Phase 2 clinical trials principally for lung cancers, however all trials were terminated or withdrawn, and further development was discontinued by the drug's sponsor, Bayer.
Mechanism Of Action and Pharmacodynamic Effects
Inhibition of the CDK kinases lead to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are often dysregulated in cancerous cells